WO2003018617A1 - Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain - Google Patents

Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain Download PDF

Info

Publication number
WO2003018617A1
WO2003018617A1 PCT/JP2002/008790 JP0208790W WO03018617A1 WO 2003018617 A1 WO2003018617 A1 WO 2003018617A1 JP 0208790 W JP0208790 W JP 0208790W WO 03018617 A1 WO03018617 A1 WO 03018617A1
Authority
WO
WIPO (PCT)
Prior art keywords
mbl
binding lectin
mannose binding
human mannose
purifying
Prior art date
Application number
PCT/JP2002/008790
Other languages
English (en)
Japanese (ja)
Inventor
Motonori Hashimoto
Naomi Asahara
Lyang-Ja Lee
Katsuki Ohtani
Original Assignee
Fuso Pharmaceutical Industries, Ltd.
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Industries, Ltd., Mitsubishi Pharma Corporation filed Critical Fuso Pharmaceutical Industries, Ltd.
Priority to JP2003523276A priority Critical patent/JP4051030B2/ja
Publication of WO2003018617A1 publication Critical patent/WO2003018617A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention vise à mettre au point un procédé permettant de purifier la lectine liant le mannose (MBL), à partir d'une matière de plasma humain, dans des rendements élevés et avec un haut degré de pureté. L'invention concerne en outre un procédé permettant de produire, en rendement élevé, une composition contenant de la MBL de haute pureté, à partir d'une matière de plasma humain, des compositions contenant de la MBL de haute pureté maintenant la structure homo-oligomère de dimension importante produite par ledit procédé, ainsi qu'une nouvelle utilisation de la MBL. Une matière de plasma humain est mise en contact avec du polyéthylène glycol, afin de donner lieu à une solution de MBL claire, utilisée comme matière pour purifier la MBL ou comme matière pour produire de la MBL. Ladite solution est ensuite soumise à une chromatographie d'affinité et à une chromatographie sur héparine. La MBL s'utilise dans la prévention ou le traitement d'infections induites par le cytomégalovirus et par le virus de l'hépatite B.
PCT/JP2002/008790 2001-08-31 2002-08-30 Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain WO2003018617A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003523276A JP4051030B2 (ja) 2001-08-31 2002-08-30 ヒトマンノース結合レクチンの精製方法、ヒトマンノース結合レクチン組成物およびヒトマンノース結合レクチンの医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-264915 2001-08-31
JP2001264915 2001-08-31

Publications (1)

Publication Number Publication Date
WO2003018617A1 true WO2003018617A1 (fr) 2003-03-06

Family

ID=19091446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008790 WO2003018617A1 (fr) 2001-08-31 2002-08-30 Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain

Country Status (2)

Country Link
JP (1) JP4051030B2 (fr)
WO (1) WO2003018617A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089394A3 (fr) * 2003-04-09 2005-08-25 Natimmune As Traitement du sars
WO2006046786A1 (fr) * 2004-10-28 2006-05-04 Dobeel Co., Ltd. Procede pour produire en masse de la lectine de liaison du mannose multimere
JP2019214555A (ja) * 2018-06-06 2019-12-19 株式会社ＭａｎａＨＳ ウイルス感染症予防用組成物
WO2021005500A1 (fr) 2019-07-09 2021-01-14 Unichem Laboratories Ltd Formulations stables de protéines recombinantes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064453A1 (fr) * 1998-06-10 1999-12-16 Statens Serum Institut Technique de purification aux fins de la production d'une lectine se fixant a la mannane (mbl) et d'un produit medical mbl
WO2000070043A1 (fr) * 1999-05-14 2000-11-23 Steffen Thiel Lectine humaine de recombinaison se fixant a la mannane
WO2002041913A1 (fr) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectines utiles comme adjuvants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064453A1 (fr) * 1998-06-10 1999-12-16 Statens Serum Institut Technique de purification aux fins de la production d'une lectine se fixant a la mannane (mbl) et d'un produit medical mbl
WO2000070043A1 (fr) * 1999-05-14 2000-11-23 Steffen Thiel Lectine humaine de recombinaison se fixant a la mannane
WO2002041913A1 (fr) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectines utiles comme adjuvants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HOHLER T. ET AL.: "No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients", EXP. CLIN. IMMUNOGENET., vol. 15, no. 3, 1998, pages 130 - 133, XP002959868 *
HOLMSKOV U. ET AL.: "Purification and characterization of bovine mannan-binding protein", GLYCOBIOLOGY, vol. 3, no. 2, 1993, pages 147 - 153, XP002959867 *
SPILLER O.B. ET AL.: "Antibody-independent activation of the classical complement pathway by cytomegalovirus-infected fibroblasts", J. INFECT. DIS., vol. 178, no. 6, 1998, pages 1597 - 1603, XP002959869 *
STORGAARD P. ET AL.: "Isolation and characterization of porcine mannan-binding proteins of different size and ultrastructure", SCAND. J. IMMUNOL., vol. 43, no. 3, 1996, pages 289 - 296, XP000911949 *
TAN S.M. ET AL.: "Improvements on the purification of mannan-binding lectin and demonstration of its Ca2+-independent association with a C1s-like serine protease", BIOCHEM. J., vol. 319, no. 2, 1996, pages 329 - 332, XP000911833 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089394A3 (fr) * 2003-04-09 2005-08-25 Natimmune As Traitement du sars
JP2006522751A (ja) * 2003-04-09 2006-10-05 ナットイムネ・アクティーゼルスカブ 重症急性呼吸器症候群（ｓａｒｓ）の処置
WO2006046786A1 (fr) * 2004-10-28 2006-05-04 Dobeel Co., Ltd. Procede pour produire en masse de la lectine de liaison du mannose multimere
JP2019214555A (ja) * 2018-06-06 2019-12-19 株式会社ＭａｎａＨＳ ウイルス感染症予防用組成物
JP7084627B2 (ja) 2018-06-06 2022-06-15 株式会社マナＨｓコーポレーション ウイルス感染症予防用組成物
WO2021005500A1 (fr) 2019-07-09 2021-01-14 Unichem Laboratories Ltd Formulations stables de protéines recombinantes

Also Published As

Publication number Publication date
JP4051030B2 (ja) 2008-02-20
JPWO2003018617A1 (ja) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2005019255A8 (fr) Muteines de la lipocaline lacrymale
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
WO2001058412A3 (fr) Extraits de residus de la production de vin
NO20022285D0 (no) Nye <alfa>-aminosyreforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
WO2001044272A3 (fr) Nouveaux lipopeptides utilises comme agents antibacteriens
HUP0402063A3 (en) Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof
EP2039699A3 (fr) Procédés d'extraction pour purifier le sucralose
DK1082293T3 (da) Formoterol-polymorfer
WO2004055006A8 (fr) Nouveaux composes presentant un effet inhibiteur selectif de la gsk3
WO2002096457A3 (fr) Formulations liquides stable s
MXPA04000756A (es) Nuevos compuestos.
BR9913026A (pt) Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
HUP0401434A3 (en) Photosensitizing agent containing sulphonated meso-tetra-phenylporphyrin, process for its preparation and pharmaceutical compositions containing thereof
DK1511761T3 (da) Fremgangsmåde til fremstilling af cykliske peptider
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2005063764A3 (fr) Nouveaux pyrrolocarbazoles fusionnes
EE200300234A (et) Bifenüülkarboksamiidühendite kasutamine lipiiditaset alandavate toimeainetena, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
NO20010522L (no) Nye piperidin-4-sulfonamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
WO2003018617A1 (fr) Procede de purification de lectine liant le mannose humain, compositions de lectine liant le mannose humain et utilisation medicale de la lectine liant le mannose humain
WO2002072803A3 (fr) Replicons sous-genomiques du la dengue a flavivirus
WO2006127990A3 (fr) Purification de thrombine
WO2001085931A3 (fr) Polypeptide inhibant un canal sodique a porte protonique
NO20016069L (no) Nye bicykliske amino-pyrazinonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdendedem
AU2002306687A1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO2005016371A8 (fr) Polypeptides de l'interferon-beta-1b humains recombinants ameliores

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003523276

Country of ref document: JP

122 Ep: pct application non-entry in european phase